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Introduction: Insulin-like growth factor-II mRNA-binding protein 3 (IMP3), a newly identiﬁed oncofetal
RNA-binding protein, plays a pivotal role in the regulation of cell growth and migration during early
stages of embryogenesis, and is found to be expressed in various human cancers. In this study, we
elucidated the clinicopathological signiﬁcance of IMP3 expression in intrahepatic cholangiocarcinoma
(ICC).
Methods: From March 1995 to December 2003, 61 surgically resected, unifocal primary ICCs were
studied. IMP3 protein expression was detected by immunohistochemical staining.
Results: IMP3 protein was expressed in 25 of 61 ICCs (41.0%). In addition to correlating with tumor grade
(p ¼ 0.0276), tumor stage (p ¼ 0.0059), lymphovascular invasion (p ¼ 0.0198), serum carbohydrate
antigen 19-9 level (p ¼ 0.0146), IMP3 expression predicted early tumor recurrence (ETR) (p ¼ 0.0059)
and was a strong indicator of worse disease-free survival (p ¼ 0.0001) and overall survival (p ¼ 0.0007).
Even though we did not ﬁnd that IMP3 expression exerted prognostic impact independent of tumor
stage, multivariate analysis conﬁrmed that IMP3 expression was an independent risk factor of high-stage
tumor and ETR (p ¼ 0.0170, and p ¼ 0.0052, respectively), and thus it contributed to poor prognosis in
ICC patients.
Conclusions: IMP3 expression can serve as a novel maker for ETR and prognostic prediction, and may be
a target for adjuvant therapy of patients with ICC after tumor resection.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most
common and a very aggressive liver cancer in adults. It accounts for
approximately 10e15% of primary liver cancers, and its incidence
has increased in recent years.1,2 Surgical resection is the only way to
provide a potential cure of the patients. Unfortunately, most lesions
are advanced at the time of diagnosis and early metastasis limitsNational Taiwan University
0051, Taiwan. Tel.: þ886 2
n).
ciates Ltd. Published by Elsevier Ltthe efﬁcacy of surgical resection. Hence, the prognosis of ICCs
remains generally poor.3,4 A number of serological and clinico-
pathological features have been shown to be prognostic factors of
surgically resectable ICC; these include HBsAg positivity, ascites,
tumor size, lymph node metastasis, perineural invasion, portal vein
invasion, intrahepatic metastasis, TNM stage, and multifocality of
tumor.2,3,5 However, useful prognostic molecular markers remain
largely unknown.
Insulin-like growth factor-II mRNA-binding protein 3 (IMP3),
also known as L523S or KOC (K-homologous domain containing
protein overexpressed in cancer),6,7 is a newly identiﬁed oncofetal
RNA-binding protein that is important in RNA trafﬁcking and
stabilization, cell growth, and cell migration during the early stages
of embryogenesis.8 The IMP3 gene is located on chromosomed. All rights reserved.
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placenta, but its expression is low or undetectable in adult tissues.8
IMP3 is widely expressed and associated with aggressive and poor
prognosis in a variety of human cancers, such as gastric adenocar-
cinoma,10 pancreatic carcinoma,11 lung carcinoma,12 esophageal
adenocarcinoma,13 breast cancer,14 osteosarcoma,15 renal cell
carcinoma,16 clear type ovarian cancer,17 endometrial serous
carcinoma,18 urothelial carcinoma,19 colon cancer,20 hepatocellular
carcinoma,21 neuroblastoma,22 and oral cancer23 but undetected in
adjacent benign tissues.6,7 Although the expression of IMP3 in
biliary tract carcinoma has been reported,24 the clinical signiﬁcance
of IMP3 expression in human ICC remains largely unclear. In this
study, we analyzed the expression of IMP3 protein by immuno-
histochemical analysis in surgically resected, unifocal primary
specimen of ICCs to elucidate its role in relation to clinicopatho-
logical features, especially early tumor recurrence (ETR), and
patient outcome.
2. Materials and methods
2.1. Tissue samples
From March 1995 to December 2003, 61 patients with surgically resected,
unifocal primary ICCs, who received detailed pathological assessments at the
National Taiwan University Hospital, Taiwan, were selected for this retrospective
study. The study was executed according to the regulations of the Ethics Committee
of National Taiwan University Hospital, and the specimens were anonymous and
analyzed in a blinded manner. These patients included 28 males and 33 females,
with a mean age of 60.8 years (range 24e88 years). All the patients had adequate
liver function reserve at the time of operation, and none had received chemotherapy
before. The distribution of tumor stage according to the TNM classiﬁcation system of
malignant tumors published by the International Union Against Cancer (UICC)25 was
as follows: stage I, n ¼ 32; stage II, n ¼ 5; stage III, n ¼ 21; and stage IV, n ¼ 3. Sixty
patients (98.4%) were followed up for at least 12 months or until death. At the end of
follow-up, 41 patients had already died.
2.2. Immunohistochemical analysis of IMP3 expression
IMP3 protein was detected on formalin-ﬁxed, parafﬁn-embedded sections by
the labeled streptavidinebiotin (LSAB) method. Brieﬂy, tissue sections (5 mm) were
dewaxed and rehydrated. Antigen retrieval was carried out by incubating the slides
in 0.01 M citric acid buffer (pH 6.0) at 100 C for 10 min. After blocking with 3% H2O2
and 5% non-immune horse serum, the slides reacted with a monoclonal antibody
against human IMP3 (L523S, DAKO Cytomation, Carpentaria, CA, USA) at a dilution
of 1:100 at 4 C overnight. The slides were then incubated with link antibodies,
followed by a peroxidase-conjugated streptavidin complex (LSAB kit, DAKO). The
peroxidase activity was visualized with diaminobenzidine tetrahydroxychloride
solution (DAB, BioGenex, San Ramon, CA, USA) as the substrate. The sections were
lightly counterstained with hematoxylin. Dark brown cytoplasmic staining was
deﬁned as positive. For negative control, we replaced the primary antibody with 5%
fetal bovine serum. The slides were examined by two pathologists (Y-M Jeng and H-
C Hsu), who were unaware of patient’s outcome.
2.3. Follow-up observation and early tumor recurrence
After surgery, the patients were regularly followed up in the outpatient clinic of
the hospital. Intrahepatic tumor recurrence or distant metastasis detected by
medical imaging within 12 months of tumor resection was deﬁned as ETR, as re-
ported previously.26
The follow-up period ranged from 3.7 to 158.4 months (average 33.5 months).
Among the patients, 56 patients (92%) had been followed up formore than 3 years or
until death, 14 patients (23%) survived for more than 5 years. All the patients were
eligible for evaluation of ETR. In the event of death, the data and the cause of death
were recorded. According to the resectability and liver function, tumor recurrence
was treated by re-resection, chemotherapy, transarterial chemoembolization or
radiofrequency ablation when feasible.
2.4. Statistical analysis
The data analyses were carried out using Epi Info (Version 3.5.1; Centers for
Disease Control and Prevention, Atlanta, GA, USA) software. Correlation between
IMP3 expression and clinicopathological variables was evaluated by using the c2 test
and Fisher’s exact test. Survival rates were calculated using the KaplaneMeier
method, and the difference in survival curves was analyzed using the log-rank
test. Multivariate survival analysis was performed on all the variables that wereanalyzed in univariate analysis. Analysis of stage was conducted by ﬁtting multiple
logistic regression models, and times to ETR and death was analyzed by ﬁtting
multiple Cox’s proportional hazard models. Two-tailed P values of <0.05 were
considered statistically signiﬁcant.3. Results
3.1. Expression patterns of IMP3 protein in ICC and liver
By immunohistochemical (IHC) stain, IMP3 protein was detec-
ted in the tumor cells in 25 of 61 ICCs (41.0%), including diffusely
positive (>50% of tumor cells) in 16 cases (26.2%), focal or hetero-
geneous (11w50% of tumor cells) in 9 cases (14.8%), which were
regarded as IMP3 positive group. Those cases without IMP3
expression or IMP3 expression in less than 10% of tumor cells were
considered as the negative group (36 cases, 59.0%). No immuno-
staining was seen in the normal or adjacent nontumorous liver
tissue (Fig. 1AeD). By means of this categorization, we found that
IMP3 expression was progressively increased with advancing
disease stage (25% in stage I, 40% in stage II, 53% in stage III, and
100% in stage IV, p ¼ 0.0087).3.2. Clinicopathological signiﬁcance of IMP3 expression in ICC
To elucidate the signiﬁcance of IMP3 protein expression in ICC
progression, we correlated with major clinicopathological vari-
ables. As shown in Table 1, IMP3 protein expression was associated
with higher serum levels of carbohydrate antigen 19e9 (CA19-9,
37 U/ml, p ¼ 0.0146), but did not correlate with age or gender.
Histologically, IMP3 protein was more frequently expressed in the
high-grade tumor (p ¼ 0.0276) and tumors with lymphovascular
invasion (p ¼ 0.0198). In addition, IMP3 expression signiﬁcantly
correlated with high-stage tumor (p ¼ 0.0059). Even though
statistically insigniﬁcant, ICCs with IMP3 expression had
a tendency to have lymph node metastasis (p ¼ 0.089).3.3. Prognostic signiﬁcance of clinicopathological variables and
IMP3 protein expression in ICC patients
As shown in Table 2, large-size tumor (>5 cm, p¼ 0.0148), high-
stage tumor (IIIeIV, p < 0.0001), lymph node metastasis
(p < 0.0001), presence of lymphovascular invasion (p ¼ 0.0277),
positive tumor margin (p¼ 0.0216), and high serum level of CA19-9
(p ¼ 0.0024) were signiﬁcant for worse disease-free survival. In
addition, large-size tumor (>5 cm, p ¼ 0.0031), tumor grade
(p ¼ 0.0412), high-stage tumor (IIIeIV, p ¼ 0.0001), lymph node
metastasis (p ¼ 0.0003), presence of lymphovascular invasion
(p ¼ 0.0319), positive tumor margin (p ¼ 0.0044), and high serum
level of CA19-9 (p ¼ 0.0004) were signiﬁcant for worse overall
survival. Most importantly, patients with IMP3 protein expression
had signiﬁcantly worse disease-free survival (Table 2 and Fig. 2A,
p ¼ 0.0001) and overall survival (Table 2 and Fig. 2B, p ¼ 0.0007).3.4. Prognostic signiﬁcance of ETR and its correlation with IMP3
expression
ETR is an important clinical factor predictive of poor prognosis
for ICC after surgical resection,26 and ETR might be regarded as an
important event before mortality. As shown in Table 2 and Fig. 3,
patients with ETR had a lower disease-free survival rate and overall
survival rate than those without ETR. (p < 0.0001, and p ¼ 0.0001,
respectively). Furthermore, patients with IMP3 expression had a 2.3
times higher incidence of ETR than ICCs without the expression
(Table 1, p ¼ 0.0059).
Fig. 1. Immunohistochemical study of insulin-like growth factor II mRNA-binding protein 3 (IMP3) protein expression in intrahepatic cholangiocarcinoma. IMP3 protein was not
expressed in adjacent nontumorous tissue (A). The proportion of tumor cells positive for IMP3 immunostain varied considerably, ranging from 10% (B), 11e50% (C), to >50% (D).
(AeD)  400 (original magniﬁcation).
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different stages
Tumor stage is the most important histological prognostic factor
of ICC.27,28 To better understand the importance of IMP3 expression
in the progression of ICC, we did combinational analyses to eluci-
date the prognostic signiﬁcance of IMP3 expression in tumors of
different stages. We found that high-stage tumor concomitant with
IMP3 expression had the worst disease-free survival and overall
survival (Fig. 4A and B; p < 0.0001 and p < 0.0001, respectively).
Notably, low-stage tumor with concomitant IMP3 expression had
signiﬁcantly worse disease-free survival than low-stage tumor
without IMP3 expression (Fig. 4A, p¼ 0.0286). Similarly, high-stage
tumor with concomitant IMP3 expression had signiﬁcantly lower
overall survival than high-stage tumor without IMP3 expression
(Fig. 4B, p¼ 0.0245). These ﬁndings suggested that IMP3 expression
determinated poor prognosis in both high- and low-stage ICCs.
3.6. IMP3 expression is an important prognostic factor of ICC
To further clarify the clinicopathological signiﬁcance of IMP3
expression in ICC, we performed a multivariate analysis. As listed in
Table 3, large tumor size (>5 cm, p ¼ 0.0013) was a signiﬁcantindependent risk factor of high-stage tumor. High tumor stage
(p ¼ 0.0131) was a signiﬁcant independent risk factor of ETR.
Importantly, we found that IMP3 expression was an independent
risk factor associated with both high tumor stage (p ¼ 0.017) and
ETR (p¼ 0.0052). Furthermore, high tumor stage and ETR were two
crucial unfavorable prognostic factors leading toworse disease-free
survival (p ¼ 0.0021 and p < 0.0001, respectively) and overall
survival (p ¼ 0.0123 and p ¼ 0.0082, respectively). However, IMP3
expression did not exert independent prognostic effect on tumor
stage or ETR. These ﬁndings suggested that IMP3 expression
contributed to poor prognosis of ICC indirectly through enhancing
tumor stage and ETR.
4. Discussion
ICC is an aggressive cancer with a dismal prognosis and the
overall 5-year survival rate of ICC is approximately 30%.27e30 Many
clinicopathological factors, such as multiplicity of lesions, tumor
grade, tumor size, vascular invasion, perineural invasion, positive
margin, lymph node metastasis, serum level of CA19-9, and intra-
hepatic metastasis are potential prognostic factors for the patients
receiving surgical resection of ICC.27e31 Consistent with previous
observations, we found that large tumor size, tumor grade,
Table 1
Univariate analysis of IMP3 protein expression with various clinicopathological




Odds ratio (95% C.I.) p value
Total Yes n (%)
Age
60 y 37 17 (46) 1.0 0.328
<60 y 24 8 (33) 1.70 (0.52e5.68)
Gender
Male 28 12 (43) 1.0 0.784
Female 33 13 (39) 1.15 (0.37e3.64)
Tumor size (cm)
5 35 12 (34) 1.0 0.217
>5 26 13 (50) 1.92 (0.60e6.19)
Tumor grade
Low 8 3 (38) 0.0276
Moderate 35 10 (29)
High 18 12 (67)
Tumor stage
IeII 37 10 (27) 1.0 0.0059
IIIeIV 24 15 (63) 4.50 (1.32e15.87)
Lymph node metastasis
No 48 17 (35) 1.0 0.089
Yes 13 8 (62) 2.92 (0.71e12.46)
Distant metastasis
No 58 23 (40) 1.0 0.745
Yes 3 2 (67) 2.88 (0.28e30.07)
Lymphovascular invasion
No 47 15 (32) 1.0 0.0198
Yes 14 10 (71) 5.33 (1.24e24.58)
Early tumor recurrence
No 37 10 (27) 1.0 0.0059
Yes 24 15 (63) 4.50 (1.32e15.87)
CA19-9  37 U/ml
No 28 7 1.0 0.0146
Yes 24 10 4.20 (1.12e16.41)
Abbreviations: C.I., Conﬁdence interval; IMP3, Insulin-like growth factor-II mRNA-
binding protein 3; CA19e9, carbohydrate antigen 19e9.
Table 2
Univariate analysis of clinicopathological variables with disease-free survival and ove
cholangiocarcinoma.
Variables n Disease-free survival
Median (months) 5-Year, n (%)
Tumor size (cm)
5 35 10.9 8 (22.9)
>5 26 5.9 2 (7.7)
Tumor grade
Low 8 30.7 2 (25.0)
Moderate 35 9.9 6 (17.1)
High 18 8.5 2 (11.1)
Tumor stage
IeII 37 18.4 10 (27.0)
IIIeIV 24 4.8 0 (0.0)
Lymph node metastasis
No 48 13.3 10 (20.8)
Yes 13 4.6 0 (0.0)
Lymphovascular invasion
No 47 10.9 10 (21.3)
Yes 14 5.5 0 (0.0)
Tumor margin
Negative 48 10.9 10 (20.8)
Positive 13 8.8 0 (0.0)
Early tumor recurrence
No 37 25.8 10 (27.0)
Yes 24 6.0 0 (0.0)
IMP3 expression
No 36 25.7 11 (30.6)
Yes 25 6.2 0 (0.0)
CA19-9  37 U/ml
No 28 22.9 8 (28.6)
Yes 24 7.5 1 (0.0)
*The P value was calculated by log-rank test.
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and serum level of CA19-9 were signiﬁcant prognostic factors of
ICC. In addition, we conﬁrmed that tumor stage is the most critical
histological prognostic factor of ICC.4,27e30 Recently, Zhou et al.
demonstrated that expression of cancer-testis antigens (CTA)
correlated with large-size tumor, and CTA was an independent
prognostic factor in 89 patients with ICC in China.32 Yonglitthipa-
gon et al. found that high expression of radixin-moesin-binding
phosphoprotein 50 and low expression of peroxiredoxin 1 corre-
lated with reduced survival in 301 liver ﬂukeeassociated chol-
angiocarcinoma in Thailand.33 Hirashita et al. reported that
expression of matrix metalloproteinase-7 correlated with poor
prognosis in 35 Japanese patients with ICC.34 However, a dramatic
difference in 5-year survival was demonstrated only for matrix
metalloproteinase-7.34 Hence, the molecular markers which are
useful to more deﬁnitely predict prognosis of ICC are still limited. In
this study, we identiﬁed IMP3 as a novel molecular marker for
prediction of tumor invasiveness and patient survival.
IMP3 is expressed in developing epithelium, muscle, and
placenta, but is expressed low or even undetectable in adult
tissues.8,35 Hence, IMP3 can be used in the discrimination of chol-
angiocarcinoma from benign bile duct lesions.36 Moreover,
concurrent use of IMP3 and S100A4 protein improves the diag-
nostic accuracy in brush cytology for pancreaticobiliary malig-
nancy.37 Immunohistochemical panel using IMP3, S100P, and von
Hippel-Lindau proteins is useful in biopsy for the diagnosis of bile
duct carcinomas.38 Furthermore, Riener et al. showed that IMP3
expressionwas found inmost of the bile duct carcinomas, including
ICC, extrahepatic cholangiocarcinoma and gallbladder carcinoma,
and signiﬁcantly correlated with poor patient survival,24 but the
prognostic signiﬁcance for each category, in particular ICC, was not
known. Therefore, we focused on the clinicopathological signiﬁ-
cance of IMP3 protein expression in ICC in this study.rall survival in 61 patients with surgical removed primary unifocal intrahepatic
Overall survival
p Value* Median (months) 5-Year, n (%) p Value*
0.0148 21.8 9 (25.7) 0.0031
11.8 2 (7.7)
0.2872 35.4 2 (25.0) 0.0412
19.3 7 (14.9)
8.6 2 (11.1))
<0.0001 23.0 10 (27.0) 0.0001
7.8 1 (4.2)
<0.0001 20.5 10 (20.8) 0.0003
7.1 1 (7.7)
0.0277 19.3 11 (23.4) 0.0319
7.8 0 (0.0)
0.0216 19.9 11 (22.9) 0.0044
11.8 0 (0.0)
<0.0001 33.8 11 (29.7) 0.0001
11.7 0 (0.0)
0.0001 31.5 11 (30.6) 0.0007
11.5 0 (0.0)
0.0024 28.4 8 (28.6) 0.0004
10.7 1 (0.0)
Fig. 2. KaplaneMeier survival curves for 61 patients with resected, unifocal, primary intrahepatic cholangiocarcinoma (ICC) in relation to the status of insulin-like growth factor II
mRNA-binding protein 3 (IMP3) expression. Patients with IMP3-positive ICCs had signiﬁcantly lower disease-free survival rate (p ¼ 0.0001) (A) And overall survival rate
(p ¼ 0.0007) (B) Than those with IMP3-negative ICCs. (þ), designated presence; (), designated absence.
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25 of 61 tumors (41%). Additionally, IMP3 expression correlated
with the serum level of CA19-9, and lymphovascular invasion,
which are factors closely related to prognosis of patients with
ICC.27e30 Because up to 30% of the ICC patients have lymph node
metastasis, and lymph node metastasis is correlated with worse
outcome, lymphadenectomy is strongly recommended.29 However,
we found that IMP3 expression only had a tendency to have lymph
node metastasis. In our series, eight of thirteen patients having
lymph node metastasis had IMP3 expressions. Remarkably, all the
eight patients having IMP3 expression died within two years after
operation, whereas two of the ﬁve patients with lymph node
metastasis but without IMP3 expression survived more than two
years, including one patient who died 66 months after resection.
However, these ﬁndings were statistically insigniﬁcant due to the
small number of cases.
IMPs have been shown to promote cell adhesion and invado-
podia formation in HeLa cells and may play a role in cell migra-
tion and invasion during development and cancer progression.39
Xenopus homolog Vg1 RNA-binding protein (Vg1-RBP) of
human IMP3 is involved in neural crest cell migration, and isFig. 3. KaplaneMeier survival curves for 61 patients with resected, unifocal, intrahepatic c
(ETR). Patients with ETR had signiﬁcantly lower disease-free survival rate (A) and overall su
designated presence; (), designated absence.necessary in regulating cell movements during both development
and metastasis.40 Recently, Samanta et al. showed that IMP3
contributes to the aggressiveness of breast carcinoma cells, and is
an effector of EGFR-mediated migration and invasion.41 We
previously showed that silencing of IMP3 in hepatocellular
carcinoma cell lines inhibited markedly the invasion capability
through the matrigel and endothelial layer.21 In addition, inhibi-
tion of IMP3 expression induces differentiation and decreases
invasive activity in neuroblastoma cell lines.22 Consistent with
these ﬁndings, we found that IMP3 expression signiﬁcantly
correlated with higher tumor grade in this study. Importantly,
IMP3 expression was associated with high-stage tumor in ICC,
which was consistent with the reports in renal cell carcinoma,
colorectal adenocarcinoma, gastric adenocarcinoma, ovarian
cancer, urothelial cancer, oral cancer, neuroblastoma, and hepa-
tocellular carcinoma.10,16,17,19e23,42 We also found that IMP3
expression also correlated with high serum level of CA19-9,
which is a valuable serological factor for predicting tumor inva-
siveness of ICC.43 Collectively, these ﬁndings indicated that IMP3
not only facilitates cell migration, tumor metastasis, but is also
associated with poor tumor differentiation.holangiocarcinoma (ICC) in relation to presence or absence of early tumor recurrence
rvival rate (B) than those without ETR (p < 0.0001 and p ¼ 0.0001, respectively). (þ),
Fig. 4. KaplaneMeier analysis of survival curves in 61patientswith orwithout insulin-like growth factor IImRNA-binding protein 3 (IMP3) expressed intrahepatic cholangiocarcinoma
(ICC) in relation to tumor stage. The p valuewas from comparison of all four groups (log rank test). (A) High-stage ICCwith concomitant IMP3 expressionwas associatedwith theworst
disease-free survival (p < 0.0001). Interestingly, low-stage ICC with concomitant IMP3 expression also had signiﬁcant worse disease-free survival than low-stage ICC without IMP3
expression (p ¼ 0.0286). (B) High-stage ICC with concomitant IMP3 expression was associated with worst overall survival (p < 0.0001), signiﬁcantly worse than ICC with high-stage
tumor without IMP3 expression (p ¼ 0.0245). (þ), designated presence; (), designated absence; L-stage, designated low-stage tumor; H-stage, designated high-stage tumor.
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surgical resection, and ETR is the major reason for a poor prog-
nosis.26 Recently, a high incidence of ETR in surgical resected ICC
has been reported.26,28,44 Therefore, the identiﬁcation of more
molecular markers will be useful for the prediction of ETR. We
showed that ICCwith IMP3 protein expression had a>2-fold higher
chance of ETR than ICC without the expression. Importantly, 23 of
the 24 patients experienced ETR died within two years after
resection. Thus, IMP3 expression may serve as a useful new
predictive molecular marker for ETR in ICC.
We found that IMP3 expression in ICC was a novel prognostic
factor, conﬁrming the observations that IMP3 is an important
prognostic factor in renal cell carcinoma, urothelial carcinoma,
hepatocellular carcinoma, neuroblastoma, and oral cancer.16,19,21eTable 3
Multivariate analyses of risk factors associated with tumor stage, early tumor
recurrence (ETR), disease-free survival (DFS), and overall survival of patients with
surgical removed primary unifocal intrahepatic cholangiocarcinoma.
Covariate Coefﬁcient S.E. Z-Statistic O.R./H.R. (95% C.I.) p Value
High stage (stage IIIA-IV) a
IMP3 1.5148 0.6345 2.3874 4.5485 (1.3115e
15.7447)
0.0170




IMP3 1.2690 0.4539 2.7955 3.5574 (1.4613e
8.6602)
0.0052




High stage 0.9816 0.3185 3.0823 2.6688 (1.4296e
4.9819)
0.0021




High stage 0.8709 0.3480 2.5024 2.3892 (1.2078e
4.7261)
0.0123
ETRb 1.0141 0.3835 2.6444 2.7569 (1.3001e
5.8459)
0.0082
Abbreviations: S.E., Standard error; O.R., Odds ratio; H.R., Hazard ratio; C.I., Conﬁ-
dence interval; IMP3, Insulin-like growth factor-II mRNA-binding protein 3.
a Multiple logistic regression model.
b Tumor recurrence within 12 months after hepatectomy.
c Multiple Cox’s proportional hazards model.23,42 Of particular interest is that, as described in pancreatic
cancer7 and in our previous study in colorectal adenocarcinoma,20
the percentage of IMP3 expression in ICC progressively increased
with advancing disease stage. In addition, we found that high-stage
tumor with concomitant IMP3 expression was associated with the
worst disease-free survival and overall survival, while low-stage
tumor without IMP3 expression had the best disease-free
survival and overall survival. Moreover, we demonstrated that
positive IMP3 expression could predict a worse disease-free
survival in patients with low-stage tumor and could predict
a worse overall survival in patients with high-stage ICC. Taken
together, these ﬁndings suggested that IMP3 may serve as a further
unfavorable prognostic maker in both patients with low-stage or
high-stage ICCs.
In conclusion, IMP3 protein expression correlated with high-
grade and high-stage tumors and ETR, and hence contributed to
poor prognosis in ICC patients. Since the expression of IMP3 is
restricted in normal mature tissues, its expression in a wide spec-
trum of cancers makes IMP3 a potential target of cancer therapy,
and deserves to be further investigated.
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